Heather McArthur, MD of Cedars-Sinai Medical Center discusses the importance of checkpoint blockade in breast cancer. With the biomarker PDL-1, there has been a 19% response rate in women with triple negative breast cancer. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
19% Response Rate for Women With Triple Negative Breast Cancer That’s Positive to the Biomarker PDL-1 Respond to Immunotherapy
